Voprosy meditsinskoi khimii最新文献

The mathematical modeling of the kinetics of riboflavin photo-chemiluminescence (PCL) in the presence of antioxidants, superoxide dismutase and ascorbic acid, has been performed. A specially developed computer program "Kinetic Analyzer" was used for the modeling. The PCL intensity of was taken as directly proportional to the superoxide concentration, because lucigenin had been added to the system. It was found, that the experimental curves of PCL virtually coincide with those calculated in the case of the following set of reactions (reaction rate constants, M-1.s-1 are given in brackets): hv + RH-->R. + .O2- (2,3 x 10(-4) s-1); RH + .O2(-)-->R. + H2O2 (1000); RH-->...(0,005 s-1); .O2- + .O2(-)-->... + phi OTOH (2 x 10(5) M-1 s-1); SOD + .O2(-)-->SOD H2O2 (1 x 10(8)); ASC + .O2(-)-->...(2 x 10(7)). Here RH is, .O2(-)--superoxide, R.--riboflavin radical, SOD--superoxide dismutase, ASC--ascorbate.

The experiments have shown that even resection of relatively small (15-20%) portion of the intact liver resulted in significant changes of glutamine metabolism in hepatocytes, which were not eliminated for 21 days of postoperative period. The changes of the activity of key enzymes of glutamine metabolism, glutamine synthetase and glutaminase (phosphate-dependent), are responsible for these alterations. The changes of activity of these enzymes closely depend on the location of hepatocytes to focus of mechanical damage.

Vanadium compounds as insulin mimics with promising therapeutic properties are reviewed. The biological effects of both inorganic forms of vanadium and vanadyl organic complexes are decried for various animal models. These effects include hypoglycemic and insulin reserve actions, insulin sensitivity enhance, cholesterol lowering and other manifestations. The effectiveness of vanadium compounds in diabetes treatment is confirmed with clinical trials. The possible mechanisms of insulin-like effects of vanadium are discussed. The various nutritional supplements for patients with diabetes mellitus including vanadium-contained used in Russia and abroad are also considered.

Experiments on chronically instrumented Wistar rats demonstrated that 15 mm microsphere embolization of coronary arteries led to a significant decrease in the systemic (APsyst) and maximal left ventricular systolic pressures (LVSPmax) to 10.1 and 21.1%, respectively (p < 0.05). To evaluate the role of endothelin in this pathology, the inhibitor of endothelin-converting enzyme (ECE), PP-36, was used. PP-36 abolished hemodynamic changes caused by embolization after 4 days per os treatment (starting 2 days before surgical procedure). Dobutamine test revealed marked decrease of LVSPmax and +dP/dtmax responses in the embolized versus sham operated animals. PP-36 normalized ischemical heart response to beta-adrenergic stimulation. Maximal APsyst and LVSPmax increases were observed in embolized rats. PP-36 abolished this effect and led to parallel rising reaction to aminoguanidin in embolized (APsyst: +12.4 +/- 1.6 vs. +6.8 +/- 2.3 mmHg, p < 0.05) as well as in sham operated rats (APsyst: +8.5 +/- 1.1 vs. +5.6 +/- 0.7 mmHg, p < 0.05). Thus, the present research showed the possibility to correct ischemical heart disturbance by using a new ECE inhibitor, PP-36. One possible mechanism of this drugs action may include systemic or myocardial changes in NO contribution to the maintenance of normal arterial pressure.

The synthesized peptides represent the functionally important site for binding to insulin receptor. Amino acids of peptide I correlate with B-chain of insulin at the position B19-B26 and A-chain at the position A20-A21. Amino acids of peptide II correlate with B-chain of insulin at position B23-B26 and A-chain at the position A20-A21. It was shown, that the these peptides increased liposomal binding followed by receptor-mediated endocytosis by cells PC12.

The conjugation of the drugs with vector molecules enables to obtain therapeutic preparation, which may be transported to the selected target organ. In the present work the methods of conjugation of antineoplastic enzyme L-lysine alpha-oxidase with antibodies were elaborated. Conjugates were worked out through the attachment of amino groups on the antibody surface either with the aldehyde groups which were created in L-lysine alpha-oxidase molecule (0.2% of initial enzymatic activity) or with the aldehyde groups of cross-linking molecules. Maximal (78%) L-lysine alpha-oxidase activity in conjugates was observed when oxidized peroxidase which contained the aldehyde groups was used as crosslinking agent. The glutaraldehyde method yielded 70% of initial enzyme activity.

The ability of protein isolated from (Trichoderma Rifai) and azydothymidine to inhibit the reproduction of HIV-virus was compared. The obtained experimental data have verified that Trichoderma Rifai protein is a promising human immunodeficiency virus (HIV) inhibitor.

Listeria monocytogenes (LM) has become a major pathogen of human foodborne illnesses eliciting meningitis, peritonitis, and abortions with a mortality rate of about 30%. During the course of the disease, LM infects a variety of tissues and cell types due to its capacity to induce its own phagocytosis even into non-phagocytic cells. For over 35 years LM continues to serve as a model to define general paradigms of immunology In this review we focus on the clinical characteristics of listeriosis, on the risk factors involved in the pathogenesis, and discuss the currently accepted approaches to prophylaxis and treatment. We report on novel strategies in vaccine development based on the LM-dependent delivering machinery for immune recognition and induction of immunological memory against desired antigens.

The modern methods of the treatment of the neurodegenerative diseases are considered. Neurodegenerative diseases originate due to the degeneration of the neuronal cells of central nervous system that leads to imbalance of the neurotransmitter synthesis and, as a consequence, movement disorders and mental disabilities. Traditional methods of pharmacotherapy and neurosurgery give short-term effect. Since 1980 neurotransplantation was developed as a new technology for the treatment of the neurodegenerative diseases. This approach represents a case of cell therapy being used for transplantation of the human fetal material. Cell transplantation compensates the local deficiency of the neurotransmitter level by substitution of degenerated neurons of patient's brain (e.g. dopaminergic neurons). Gene-cell conjunction of cell therapy with modification of genome of transplanted cells is the most perspective approach to increase an efficiency of neurotransplantation. Short description of gene therapy approaches and a search for optimal gene-cell protocols for therapy of neurodegenerative diseases are presented in this paper.